Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Esophageal Cancer: early-phase trial registry
63 of 132 indexed Esophageal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #88 of 28,707 conditions by registered trial count.
132 US clinical trials · 63 currently recruiting · #88 of 28,707 conditions by registered trial count
Esophageal Cancer: 132 US clinical trials tracked, 63 recruiting.
Esophageal Cancer is the subject of 132 registered US clinical trials on ClinicalTrials.gov, 63 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 10 of these trials.
Enrollment posture brief
Registry condition esophageal-cancer
OPEN 63 | RECR 48% | LATE 8 | EARLY 84 | RANK #88 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Alcohol Drinking (48% recruiting · 86 trials)
Esophageal Cancer lists 63 open slots (48% of 132 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Esophageal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Esophageal Cancer is recruiting above its size-band peers.
63 of 132 indexed trials (47.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Esophageal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 10 of 132 trials (7.6%). 89 distinct sponsors appear on at least one study for this condition label.
-
Typical Esophageal Cancer enrolment sits around 80 participants.
Median target enrolment is 80 among the 124 trials that report a genuine target (sentinel values excluded). 69 of those (55.6%) plan for fewer than 100 participants.
-
Esophageal Cancer research is mostly interventional.
106 interventional and 26 observational studies make up this index (80.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
132 total, page 1 of 3
Integrated Cancer Repository for Cancer Research
University of Nebraska
NCT02012699
Esophageal Cancer Risk Registry
University of Pittsburgh
NCT00260585
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Adela
NCT05366881
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Vanderbilt University Medical Center
NCT00899626
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
University of Colorado, Denver
NCT02634645
Retrospective Review of Esophageal Cancer at MSKCC
Memorial Sloan Kettering Cancer Center
NCT05706558
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
University of Pittsburgh
NCT00260559
EsophaCap for the Detection of Early Esophageal Carcinoma
Johns Hopkins University
NCT04214119
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
NCT07431281
Pan-tumor MRD Study
Paradigm Health
NCT06605404
Mayo Clinic Upper Digestive Disease Survey
Mayo Clinic
NCT02530983
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT06172478
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
University of Colorado, Denver
NCT00900419
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
University of Missouri-Columbia
NCT02838836
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
NCT03526835
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06238479
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT07223424
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune
NCT05983432
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT05581004
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06465069
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
University of Colorado, Denver
NCT05517811
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
University of Missouri-Columbia
NCT03551951
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT07090499
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
University of California, Davis
NCT06101277
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
Resilience and Equity in Aging, Cancer, and Health (REACH)
Dana-Farber Cancer Institute
NCT04674267
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology
NCT03556228
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Merck Sharp & Dohme
NCT06445972
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
SOFIE
NCT07217704
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Phrontline Biopharma
NCT07181473
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
Northwestern University
NCT05056051
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NCT06263088
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT06695845
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Merck Sharp & Dohme
NCT06469944
Serial MRI Scans During Radiation Therapy
Dana-Farber Cancer Institute
NCT04188535
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies
NCT06047379
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06239194
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT06710756
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
NCT04354064
DESTINY-PANTUMOUR04
AstraZeneca
NCT07124000
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Stanford University
NCT01048281
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
M.D. Anderson Cancer Center
NCT06181656
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Lumicell
NCT02584244
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
M.D. Anderson Cancer Center
NCT06414902
Registry for Esophageal and Gastroesophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
NCT06558786
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
John Waters
NCT07039526
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
Medical College of Wisconsin
NCT06906887
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT06123338
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 49 |
| Phase 2 | 35 |
| Phase 3 | 5 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Esophageal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Esophageal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Esophageal Cancer page
132 registered trials, 63 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 63 Esophageal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Esophageal Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Esophageal Cancer condition card totals 132 registered trials; most-linked intervention radiation therapy; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.